MacroGenics IncNASDAQ:MGNX
- LAST PRICE4.2850
- TODAY'S CHANGE (%)-0.0650 (-1.4943%)
- Bid / Lots4.2800/ 7
- Ask / Lots4.2900/ 8
- Open / Previous Close4.3900 / 4.3500
- Day Range
- 52 Week Range
- Volume312,584
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGNX |
|---|---|---|
| 09:32 ET | 4633 | 4.3219 |
| 09:33 ET | 2600 | 4.29 |
| 09:35 ET | 1300 | 4.32 |
| 09:37 ET | 2900 | 4.345 |
| 09:39 ET | 2897 | 4.3658 |
| 09:42 ET | 4250 | 4.33 |
| 09:44 ET | 1675 | 4.32 |
| 09:46 ET | 4337 | 4.275 |
| 09:48 ET | 5440 | 4.235 |
| 09:50 ET | 8436 | 4.22 |
| 09:51 ET | 2341 | 4.245 |
| 09:53 ET | 2168 | 4.255 |
| 09:55 ET | 2800 | 4.2594 |
| 09:57 ET | 1784 | 4.25 |
| 10:00 ET | 3258 | 4.255 |
| 10:02 ET | 2045 | 4.22 |
| 10:04 ET | 2200 | 4.225 |
| 10:06 ET | 300 | 4.2194 |
| 10:08 ET | 5499 | 4.235 |
| 10:09 ET | 3700 | 4.22 |
| 10:11 ET | 1000 | 4.245 |
| 10:13 ET | 3666 | 4.23 |
| 10:15 ET | 400 | 4.235 |
| 10:18 ET | 378 | 4.24 |
| 10:20 ET | 3010 | 4.2217 |
| 10:22 ET | 1400 | 4.22 |
| 10:24 ET | 700 | 4.23 |
| 10:26 ET | 400 | 4.245 |
| 10:27 ET | 700 | 4.24 |
| 10:29 ET | 2400 | 4.24 |
| 10:31 ET | 1994 | 4.225 |
| 10:33 ET | 1577 | 4.246 |
| 10:36 ET | 724 | 4.2512 |
| 10:38 ET | 2303 | 4.255 |
| 10:40 ET | 225 | 4.2512 |
| 10:42 ET | 1500 | 4.2475 |
| 10:44 ET | 3368 | 4.24 |
| 10:45 ET | 700 | 4.225 |
| 10:47 ET | 100 | 4.225 |
| 10:49 ET | 300 | 4.22 |
| 10:51 ET | 901 | 4.215 |
| 10:54 ET | 1235 | 4.23 |
| 10:56 ET | 400 | 4.22 |
| 10:58 ET | 2741 | 4.22 |
| 11:02 ET | 200 | 4.225 |
| 11:03 ET | 1489 | 4.23 |
| 11:05 ET | 1989 | 4.245 |
| 11:07 ET | 2139 | 4.25 |
| 11:09 ET | 800 | 4.255 |
| 11:12 ET | 4352 | 4.2412 |
| 11:14 ET | 500 | 4.245 |
| 11:16 ET | 400 | 4.245 |
| 11:18 ET | 4838 | 4.25 |
| 11:20 ET | 3683 | 4.26 |
| 11:21 ET | 245 | 4.252 |
| 11:23 ET | 5135 | 4.27 |
| 11:25 ET | 1100 | 4.265 |
| 11:27 ET | 200 | 4.265 |
| 11:30 ET | 3240 | 4.26 |
| 11:32 ET | 1900 | 4.245 |
| 11:34 ET | 700 | 4.245 |
| 11:36 ET | 400 | 4.245 |
| 11:38 ET | 100 | 4.245 |
| 11:39 ET | 1600 | 4.255 |
| 11:41 ET | 608 | 4.25 |
| 11:43 ET | 1672 | 4.245 |
| 11:45 ET | 11802 | 4.2425 |
| 11:48 ET | 300 | 4.245 |
| 11:50 ET | 3905 | 4.245 |
| 11:52 ET | 1100 | 4.235 |
| 11:54 ET | 5494 | 4.23 |
| 11:56 ET | 8665 | 4.25 |
| 11:57 ET | 800 | 4.235 |
| 11:59 ET | 1010 | 4.2419 |
| 12:01 ET | 200 | 4.245 |
| 12:03 ET | 1866 | 4.25 |
| 12:06 ET | 200 | 4.245 |
| 12:08 ET | 4174 | 4.255 |
| 12:10 ET | 7171 | 4.275 |
| 12:12 ET | 2299 | 4.29 |
| 12:14 ET | 1662 | 4.301 |
| 12:15 ET | 1900 | 4.3 |
| 12:17 ET | 1600 | 4.315 |
| 12:19 ET | 1820 | 4.295 |
| 12:21 ET | 550 | 4.29 |
| 12:24 ET | 490 | 4.2801 |
| 12:26 ET | 671 | 4.275 |
| 12:28 ET | 500 | 4.28 |
| 12:30 ET | 100 | 4.275 |
| 12:32 ET | 400 | 4.275 |
| 12:33 ET | 570 | 4.275 |
| 12:35 ET | 600 | 4.275 |
| 12:37 ET | 100 | 4.275 |
| 12:39 ET | 200 | 4.275 |
| 12:42 ET | 529 | 4.275 |
| 12:44 ET | 1085 | 4.265 |
| 12:46 ET | 700 | 4.28 |
| 12:48 ET | 230 | 4.28 |
| 12:50 ET | 200 | 4.275 |
| 12:51 ET | 300 | 4.275 |
| 12:53 ET | 600 | 4.285 |
| 12:55 ET | 900 | 4.28 |
| 12:57 ET | 100 | 4.2801 |
| 01:02 ET | 1766 | 4.27 |
| 01:04 ET | 1300 | 4.255 |
| 01:08 ET | 900 | 4.235 |
| 01:09 ET | 900 | 4.22 |
| 01:11 ET | 1400 | 4.21 |
| 01:13 ET | 1300 | 4.1905 |
| 01:18 ET | 676 | 4.2 |
| 01:20 ET | 300 | 4.19 |
| 01:22 ET | 200 | 4.195 |
| 01:24 ET | 491 | 4.185 |
| 01:26 ET | 300 | 4.185 |
| 01:27 ET | 3252 | 4.195 |
| 01:29 ET | 200 | 4.195 |
| 01:31 ET | 800 | 4.195 |
| 01:33 ET | 3748 | 4.2 |
| 01:36 ET | 830 | 4.215 |
| 01:44 ET | 2253 | 4.205 |
| 01:45 ET | 1254 | 4.22 |
| 01:47 ET | 200 | 4.225 |
| 01:49 ET | 412 | 4.235 |
| 01:51 ET | 100 | 4.239 |
| 01:56 ET | 802 | 4.255 |
| 01:58 ET | 2950 | 4.273309 |
| 02:00 ET | 400 | 4.2754 |
| 02:02 ET | 2071 | 4.265 |
| 02:03 ET | 100 | 4.265 |
| 02:05 ET | 1797 | 4.2725 |
| 02:07 ET | 700 | 4.285 |
Nov 7, 2024
Attention Macrogenics, Inc. (MGNX) Shareholders: Grabar Law Office Investigates Potential Claims on Your Behalf, from 10:00PM ET on Thursday Nov 07, 2024 by Dow Jones
10:00PM ET on Thursday Nov 07, 2024 by Dow JonesDJ Macrogenics Cut to Market Perform From Market Outperform by JMP Securities, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
MacroGenics to Participate in Upcoming Investor Conferences, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ Macrogenics Price Target Maintained With a $4.00/Share by HC Wainwright & Co., from 7:35AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:35AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MacroGenics Inc | 273.0M | -2.7x | --- |
Fate Therapeutics Inc | 275.6M | -1.4x | --- |
Poseida Therapeutics Inc | 299.1M | -3.0x | --- |
ADC Therapeutics SA | 283.3M | -1.1x | --- |
Adaptimmune Therapeutics PLC | 203.8M | -2.4x | --- |
AVITA Medical Inc | 310.6M | -5.4x | --- |
Company Information
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Contact Information
- Headquarters
- 9704 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 301-251-5172
- Fax
- 301-251-5321
Executives
- Independent Chairman of the Board
- William Heiden
- President, Chief Executive Officer, Director
- Scott Koenig
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- James Karrels
- Chief Operating Officer
- Eric Risser
- Senior Vice President - Research, Chief Scientific Officer
- Ezio Bonvini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $273.0M |
|---|---|
Revenue (TTM) | $141.3M |
Shares Outstanding | 62.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.09 |
EPS | $-1.57 |
Book Value | $2.46 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -75.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
